🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to health experts.

An International Health Concern

Gonorrhoea infections are on the rise worldwide, with estimates suggesting over 82 million instances annually. Particularly high rates are seen in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the context of increasing worldwide cases, escalating drug resistance and the highly restricted therapeutic options presently on offer.”

Health officials are increasingly worried about the surge in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". Ongoing monitoring revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Receive Clearance

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to major issues, including infertility. Scientists believe that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, was also approved in concurrent days. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to see it through.

“This authorization represents a huge turning point in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Testing Outcomes and Worldwide Availability

As per findings released by a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The research included over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the authority to register and commercialise the drug in many low-income and middle-income countries.

Medical professionals directly involved have voiced positive views. Access to a easy-to-administer therapy such as this is hailed as a "critical tool" for gonorrhoea control. This is deemed essential to reduce the burden of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.